JOIN US

Where Leaders in Healthcare Innovation Converge

2024 PROGRAM iS NOW SOLD OUT
REQUEST AN INVITATION for 2025

leaders shaping our 2024 program:

Jake Auchincloss

U.S. Representative,

U.S. Congress

Jake Auchincloss

Katrine Bosley

Founding CEO,

DaCapo Brainscience

Katrine Bosley

Ryan Brady

Head of Global Dis. Bus. Dev.,

Evotec

Ryan Brady

Christine Brennan, PhD

Managing Director,

Vertex Ventures HC

Christine Brennan, PhD

Julianne Bruno

Senior Vice President,

CRISPR Therapeutics

Julianne Bruno

Abe Ceesay

CEO,

Rapport Therapeutis

Abe Ceesay

Cynthia Clayton

VP, Comms & Inv. Rels,

Third Rock Ventures

Cynthia Clayton

Joe Colaiano

Associate Chief Legal Officer,

Mayo Clinic

Joe Colaiano

Steve Dickman

CEO,

CBT Advisors

Steve Dickman

Katie Ellias, PhD

Managing Director,

JRDF T1D Fund

Katie Ellias, PhD

Pushkal Garg, MD

Chief Medical Officer,

Alnylam Pharmaceuticals

Pushkal Garg, MD

Michael Gilman, PhD

CEO,

Arrakis Therapeutics

Michael Gilman, PhD

Yvonne Hao

Secretary of Economic Dev.,

Commonwealth of MA

Yvonne Hao

John Higgins

Managing Director,

Brain Tumor Investment Fund

John Higgins

Colin Hill

CEO, Aitia

Colin Hill

Anna Huyghues-Despointes

Chief Corp Dev. Officer,

Owkin

Anna Huyghues-Despointes

Donald Ingber, MD, PhD

Founding Director,

Wyss Institute

Donald Ingber, MD, PhD

Steve Kafka, PhD

General Partner.

Section 32

Steve Kafka, PhD

Rosana Kapeller, MD, PhD

President & CEO,

ROME Therapeutics

Rosana Kapeller, MD, PhD

Jeff Karp, PhD

Distinguished Professor,

Brigham and Women’s Hospital

Jeff Karp, PhD

Shahar Keinan, PhD

CEO and co-founder,

POLARISqb

Shahar Keinan, PhD

Jeb Keiper

CEO,

Nimbus Therapeutics

Jeb Keiper

Rich Kivel

Managing Director,

GrayBella Capital

Rich Kivel

Peter Kolchinsky, PhD

Managing Partner,

RA Capital Management

Peter Kolchinsky, PhD

Ivana Magovcevic-Liebisch, PhD

CEO and President,

Vigil Neuroscience

Ivana Magovcevic-Liebisch, PhD

Fiona Marshall, PhD

President, Biomedical Research,

Novartis

Fiona Marshall, PhD

Jodie Morrison

Atlas Ventures Advisor,

Acting CEO Q32

Jodie Morrison

Marian Nakada

Johnson & Johnson Innov.

- JJDC

Marian Nakada

Amir Nashat, PhD

Executive Partner,

Polaris Partners

Amir Nashat, PhD

Stephanie Oestreich, PhD

Managing Director,

Myeloma Investment Fund

Stephanie Oestreich, PhD

Gilmore O'Neill

President & CEO,

Editas

Gilmore O'Neill

Steve Pagliuca

Executive Chair,

Arena BioWorks

Steve Pagliuca

Robert Plenge, MD, PhD

EVP, Chief Research Officer,

Bristol Myers Squibb

Robert Plenge, MD, PhD

Alice Pomponio

Managing Director,

BrightEdge - American Cancer Society

Alice Pomponio

Anna Protopapas

Board of Directors,

Mersana Therapeutics

Anna Protopapas

Jigar Raythatha

Partner,

Third Rock Ventures

Jigar Raythatha

Kiran Reddy, MD

Sr. Managing Director,

Blackstone Life Sciences

Kiran Reddy, MD

Rosemary Reilly

Partner,

WilmerHale

Rosemary Reilly

Riccardo Sabatini, PhD

Chief Data Scientist,

Orionis Biosciences

Riccardo Sabatini, PhD

Woody Sherman, PhD

CEO,

Psivant Therapeutics

Woody Sherman, PhD

Allen Smith, MD

President/CEO,

South Shore Health

Allen Smith, MD

John Stanford

Executive Director,

Incubate Coalition

John Stanford

Ramita Tandon

Chief Clin. Trials Off.,

Walgreens Boots Alliance

Ramita Tandon

Alison Taunton-Rigby

Director and Trustee,

Healthcare, Life Sci. & Financial Svs

Alison Taunton-Rigby

Anna Turetsky, PhD

Principal, Venture Invest.,

The Mark Foundation

Anna Turetsky, PhD

Larry Vernaglia

Partner,

Foley and Lardner, LLP

Larry Vernaglia

Meg Wood

Managing Director,

NYBC Ventures

Meg Wood

Daphne Zohar

Founder & CEO,

Seaport Therapeutics

Daphne Zohar

visit THE 2023 CONVERGENCE FORUM

“I absolutely loved attending the event this year (my first) and will positively join in 2024.” - 2023 Participant

blue water bkgrd_sm.png